Spago Nanomedical AB Sustainability Reports
Spago Nanomedical AB is a clinical-stage nanomedicine company that develops polymeric nanomaterial platforms for cancer diagnostics and treatment. Its key development programs include Tumorad for radionuclide therapy and SpagoPix for targeted tumor-selective magnetic resonance imaging contrast.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300DNLTVJ4OGO5X40
FIGI: BBG003Q0FJD2
14 reports from 2016 to 2025